What ought to traders do when shares are tanking over the quick time period? Most likely one of the best reply is to assume long run.
Three Motley Idiot contributors assume they’ve discovered nice dividend stocks to personal for the long run that pay you to attend for higher days. This is why they picked AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Eli Lilly (NYSE: LLY).
Keith Speights (AbbVie): Not like most shares, AbbVie’s share worth is up by a double-digit proportion to date in 2025. Traders know that the large pharmaceutical firm’s merchandise will likely be in demand, no matter what occurs with the economic system or the inventory market.
I like AbbVie’s resilience. The corporate is coming off the patent expiration for its longtime top-selling drug, Humira. However AbbVie deliberate exceptionally effectively for this lack of exclusivity. Its two successors to Humira (Rinvoq and Skyrizi) are on observe to generate extra gross sales mixed than Humira did at its peak.
AbbVie has additionally accomplished a number of necessary acquisitions lately. These offers added main development drivers to the corporate’s lineup, together with most cancers drug Elahere, beauty remedy Botox, and antipsychotic Vraylar.
As well as, AbbVie’s pipeline seems to be promising. The corporate has over 90 packages in medical improvement, together with late-stage candidates equivalent to autoimmune illness drug lutikizumab and a number of myeloma drug etentamig.
Arguably one of the best factor about AbbVie, although, is its dividend. The drugmaker’s ahead dividend yield stands at 3.25%. AbbVie can also be a Dividend King, with 53 consecutive years of dividend will increase.
Prosper Junior Bakiny (Amgen): Biotech large Amgen has seen its share of points lately. It has typically had bother rising its natural income quick at a good-enough clip for traders’ liking, and late final 12 months, the drugmaker confronted a medical setback when its investigational weight administration medication, MariTide, did not perform as well as expected in phase 2 studies. Nonetheless, these points do little to vary Amgen’s long-term prospects.
The corporate’s lineup has gotten stronger, partly because of acquisitions. It has development drivers like Tepezza, a drugs for thyroid eye illness; bronchial asthma medication Tezspire; and others. Amgen’s gross sales development is secure and may enhance as the corporate earns approval for newer merchandise and lands label expansions for current ones. Additional, Amgen’s pipeline is not restricted to MariTide — by no means thoughts that this program may nonetheless make waves within the fast-growing weight reduction market.
Past that, Amgen has greater than 30 candidates in part 3 research alone. The biotech ought to have little bother replenishing its lineup and sustaining regular income and earnings development, simply because it has over the long term.
Amgen has additionally constantly raised its dividends. Its payouts have grown by 201% prior to now decade. The corporate’s ahead yield of three.1% beats the S&P 500‘s (SNPINDEX: ^GSPC) common of 1.3%.
Amgen has to date defied the market sell-off now we have skilled this 12 months. Whether or not or not it continues to take action, the inventory is a wonderful possibility for income-seeking traders.
David Jagielski (Eli Lilly): In the event you’re searching for a high dividend inventory to personal, you could be tempted to skip over Eli Lilly as a consequence of its low yield of lower than 1%. However doing so could possibly be a mistake. That is as a result of whereas its yield is low right this moment, the dividend has been rising considerably over time.
At the moment, the corporate pays traders a quarterly dividend of $1.50, which is greater than twice what it was paying 5 years in the past. Again then, the quarterly payout was $0.74. The corporate has elevated its dividend by 15% for seven consecutive years.
The inventory could be yielding a a lot increased fee if not for its skyrocketing valuation. In 5 years, it has risen by 480% in worth and while you embrace its dividend, traders’ complete returns are up round 533%. By comparability, the S&P 500’s complete returns over that stretch are 135%.
Eli Lilly isn’t just a improbable development inventory with unimaginable belongings in Zepbound and Mounjaro, that are GLP-1 medication producing billions in income for the enterprise, but it surely’s additionally a terrific dividend development inventory to hold on for 10-plus years. The inventory could look costly, buying and selling at near 70 instances its trailing earnings, however with a fast-growing enterprise and a stellar dividend, that is an funding that may be an incredible match for any portfolio.
Before you purchase inventory in AbbVie, think about this:
The Motley Idiot Inventory Advisor analyst crew simply recognized what they consider are the 10 best stocks for traders to purchase now… and AbbVie wasn’t one among them. The ten shares that made the reduce may produce monster returns within the coming years.
Contemplate when Netflix made this listing on December 17, 2004… if you happen to invested $1,000 on the time of our advice, you’d have $461,558!* Or when Nvidia made this listing on April 15, 2005… if you happen to invested $1,000 on the time of our advice, you’d have $578,035!*
Now, it’s price noting Inventory Advisor’s complete common return is 730% — a market-crushing outperformance in comparison with 147% for the S&P 500. Don’t miss out on the most recent high 10 listing, obtainable while you be a part of Inventory Advisor.
See the 10 stocks »
*Inventory Advisor returns as of April 5, 2025
David Jagielski has no place in any of the shares talked about. Keith Speights has positions in AbbVie. Prosper Junior Bakiny has positions in Eli Lilly. The Motley Idiot has positions in and recommends AbbVie and Amgen. The Motley Idiot has a disclosure policy.
3 Dividend Stocks to Buy and Hold for the Next Decade was initially printed by The Motley Idiot
